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Dr Leonard N. Girardi (New York, NY). I congratulate Dr La-
Par for an excellent presentation and the University of Virginia
group for outstanding results in a patient population that we are
all seeing more of, those with previous cardiac surgery now requir-
ing AVR. The 2% mortality in their last 100 cases is truly remark-
able, actually lower than their mortality among patients undergoing
primary AVR. To help us to learn more from their experience and
perhaps incorporate some of their experiences and recommenda-
tions into our own practice, I have a few questions.
Dr LaPar, you were correct in assigning some of the credit for
this improvement in mortality with time to improved surgical tech-
nique and a larger hospital experience with this patient population.
The patients in the last era, however, about the last 100 patients, ac-
tually had better New York Heart Association functional class, had
higher ejection fraction, underwent fewer urgent operations, and
underwent fewer concomitant mitral valve and CABG procedures
at the time of reoperative AVR. So, are we truly technically better
than we were in a previous era, or are we just better at getting pa-
tients to the operating room earlier? That would include educating
our cardiology counterparts in getting patients to the operating
room earlier. Also, once we get them to the operating room, are
we a little smarter not so much in how we do the operation techni-
cally but perhaps in what we don’t do to the mitral valve and to the
coronaries, to cut down on the increased crossclamp and bypass
times that so significantly contributed to mortality in your series?
Dr LaPar. Dr Girardi, thank you for the feedback and those in-
sightful questions. Certainly, patient selection is fundamental in im-
proving operative outcomes and mortality. In this study, we believe
that the trends that we had seen in declining operative mortality andThe Journal of Thoracic and Caoutcomes are likely related to a combination of several factors. As
you mentioned, we performed significantly more reoperative AVRs
in the most recent era. We believe that as we do more surgery, we
are getting better. In addition, the change in our surgical technique
to include a minimal dissection of the heart has contributed to
shorter aortic crossclamping and cardiopulmonary bypass times.
We feel that these effects are significant in our results. We also,
in the most recent times, have obtained more preoperative com-
puted tomographic angiograms to help us to define vein graft anat-
omy better, as well as cardiac and mediastinal anatomy, and we
believe that this may help in that patient selection and also in our
operative planning. Finally, improvements in cardiac anesthesia
and postoperative care with time have likely resulted in benefits
for all cardiac operations.
With respect to preoperative risk, you mentioned ejection frac-
tion and New York Heart Association functional class. We primar-
ily thought to evaluate preoperative risk with EuroSCORE, and we
did find higher EuroSCOREs in the most recent operative era. We
consider higher EuroSCOREs to be representative of a sicker and
older population in the most recent era. To rule out the effects of
concomitant operations, we thought it was important to look at
the isolated reoperative AVR group. We showed nearly identical
trends and improved mortality within that group as well.
Dr Girardi. Second, and finally, if open reoperative AVR is to
remain competitive with the less invasive approaches that we heard
about earlier today, transapical and transfemoral AVR, especially
in reoperations where they may actually have some obvious bene-
fits, we have to continue to work on reducing the morbidity and
mortality. The number one cause of mortality in your series was
bleeding and post operative tamponade. Although in the last era
you had a remarkable 5% reoperation or reexploration rate for
bleeding, 43% of the deaths in this series were from tamponade
and bleeding. So how are you handling that? Also, should we actu-
ally be a bit more aggressive and liberal about taking patients back
for bleeding to avoid those catastrophic consequences of massive
transfusion and unrecognized tamponade?
Dr LaPar. We could not agree more. At our institution, we per-
form early reexploration for all suspected cases of persistent post-
operative bleeding or tamponade. Specifically, we perform early
reexploration in the intensive care unit with standard operating
room equipment, personnel, and procedure. Our philosophy is
that early reexploration will prevent further postoperative compli-
cations and improve patient outcome. Furthermore, we believe
that the higher postoperative bleeding rates of our earlier operative
eras is related to more complex dissections in the past.
Dr Anthony L. Estrera (Houston, Tex). I congratulate you
on a nice presentation. In doing reoperative cardiac surgery,
we also apply this minimal dissection, or what I call directed dis-
section. More than half your cases had previous CABG. So
my question is, how did you deal with the patent left internal
thoracic artery?
Dr LaPar. Thank you for that question. One of the more recent
philosophic changes in our operative techniques is that we do not
routinely clamp the internal thoracic artery during reoperations.
In fact, we recently published a series looking at this issue and
found no difference in outcome or mortality with this technique.
In adopting this approach, we have attained equal results while at
the same time simplifying the operation and avoiding internal tho-
racic artery injury.rdiovascular Surgery c Volume 139, Number 2 271
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DDr Sacha Salzberg (Zurich, Switzerland). Thank you for this
nice presentation. I have a question regarding the technique of can-
nulation and how that has evolved with time. Have you used axil-
lary cannulation? If so, how has that influenced outcomes and
neurologic complications?
Dr LaPar. In this study, we did not specifically evaluate out-
comes according to cannulation technique. We routinely use preop-272 The Journal of Thoracic and Cardiovascular Surgerative computed tomographic angiography and intraoperative
ultrasonography, however, to survey the ascending aorta to select
an appropriate aortic cannulation site. Almost all the cases included
in this study involved direct aortic cannulation. For cases in which
aortic cannulation is difficult, we favor such approaches as axillary
or innominate cannulation.ery c February 2010
